Abstract-c-Src plays an important role in angiotensin II (Ang II) signaling. Whether this member of the Src family kinases is involved in the development of Ang II-induced hypertension and associated cardiovascular damage in vivo remains unknown. Here, we studied Ang II-infused (400 ng/kg/min) mice in which c-Src was partially deleted (c-Src 
H ypertension is associated with vascular damage characterized by impaired endothelial function and arterial remodeling. 1, 2 Many factors underlie these processes, including angiotensin II (Ang II), a particularly important vasoactive peptide in human and experimental hypertension. Ang II regulates vascular function and structure by activating complex signaling pathways inducing contraction, cell growth, inflammation, and fibrosis. 3, 4 Common to these processes is generation of reactive oxygen species (ROS), including superoxide anion and hydrogen peroxide (H 2 O 2 ), and activation of redox-sensitive kinases. 5, 6 ROS function as intracellular second messengers to stimulate mitogen-activated protein kinases (MAPKs), tyrosine kinases, and transcription factors and inactivate protein tyrosine phosphatases. 7, 8 ROS also increase intracellular calcium and activate proinflammatory transcription factors. 9, 10 NADPH oxidases (Nox), the major source of ROS in the vasculature, are tightly regulated by Ang II in vitro and in vivo. [11] [12] [13] Mechanisms linking Ang II to Nox and upstream signaling kinases in vascular cells have received considerable attention. 14, 15 Of particular importance in the vasculature is c-Src, a member of the Src kinase family of nonreceptor tyrosine kinases, key proximal regulators of Nox-driven superoxide anion generation, and MAPK activation. [16] [17] [18] Src family protein kinases are proto-oncogenes involved in cell morphology, motility, proliferation, and survival. 19, 20 There are 11 members of the Src family in humans, of which c-Src, Fyn, and Yes are ubiquitously expressed. The 60-kDa c-Src, the prototype, is highly expressed in the vasculature, involved in redox signaling associated with vascular function, and rapidly activated by vasoactive agents, including Ang II.
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We previously reported that c-Src plays a major role in Ang II signaling. [21] [22] [23] In vascular smooth muscle cells (VSMCs) from human resistance arteries, Ang II induces c-Src phosphorylation to produce superoxide anion via Nox activation. [24] [25] [26] Of clinical relevance, our studies demonstrated the contribution of c-Src in molecular and cellular processes underlying Ang II-mediated vascular changes that occur in human hypertension. [24] [25] [26] [27] In further support of a role for Src kinases in Ang II-dependent hypertension, Qin and Zhou 28 demonstrated that pharmacological inhibition of Src family kinases prevented development of hypertension and reduced vascular smooth muscle myosin light chain phosphorylation in Ang II-infused mice. However, to our knowledge, it is still unclear whether c-Src is specifically implicated. Moreover, mechanisms whereby c-Src influences cardiovascular function in vivo remain to be elucidated.
In the present in vivo study, we focused on c-Src as a major player in vascular injury and target organ damage in Ang II-induced hypertension. We also explored putative molecular mechanisms, specifically ROS, and proinflammatory and profibrotic signaling pathways, whereby c-Src regulates cardiovascular function in hypertension.
Methods
Methods are available in the online-only Data Supplement.
Animals
Genetic and pharmacological strategies were used to downregulate c-Src in mice. First, we studied wild-type (WT; c-Src
) and heterozygous (c-Src
) male mice 29 infused with Ang II (400 ng/kg/min,10-12 days). c-Src −/− mice have osteopetrosis with poor survival and hence were not studied. In some experiments, we infused norepinephrine (NE; 3.8 µg/kg/min) to assess whether c-Src effects are Ang II specific or generalized. Second, we used a pharmacological approach to inhibit c-Src. Ang II-infused WT mice received daily injections of a c-Src inhibitor, CGP077675 (25 mg/kg/d, 7 days), 30 started 5 days after initiation of Ang II infusion. At study end, plasma, aorta, mesenteric arteries, and heart were collected. Systolic blood pressure (SBP) was assessed by tail-cuff plethysmography and telemetry. 11, 31 .
Plasma Biochemistry
Plasma glucose, triglycerides, and cholesterol were determined by automated analyzer.
Echocardiography
Cardiac geometry and function were evaluated by echocardiography. 32 
Assessment of Vascular Function, Structure, and Mechanics
Second-order branches of the superior mesenteric artery were mounted in a pressure myograph, and function, structure, and mechanics studied. 33 
ROS Assessment
Vascular ROS generation was measured by lucigenin chemiluminescence and dihydroethidium fluorescence. Systemic oxidative stress was determined by quantifying plasma thiobarbituric acid-reactive substance levels and by amplex red. 7, 11 
Western Blotting
Vascular protein was extracted and immunoblotted as described. 
Histological and Immunohistochemical Analyses
Heart and aortic tissues were stained with Masson trichrome or Sirius Red, and macrophages labeled with CD68-antibody.
Statistics
Data are presented as means±SEM. Groups were compared using 1-way ANOVA, 2-way ANOVA, or t test as appropriate. P<0.05 was considered significant. Table S1 in the online-only Data Supplement demonstrates morphological and metabolic characteristics. Ang II increased heart mass in WT but not in c-Src +/− mice. Metabolic parameters were similar between groups (Table S2) .
Results
Mouse Characteristics
Ang II-Induced Cardiac Dysfunction Is Ameliorated in c-Src +/− Mice
Ang II-infused WT mice exhibited reduced fractional shortening and increased IVSd (interventricular septal end diastole) and LVPWd (left ventricular posterior wall diastole) (Table S3) .
Ang II-Induced Hypertension Is Blunted in c-SrcDeficient Mice
Ang II increased SBP in WT mice ( Figure 1A ). In
c-Src
+/− mice, Ang II-induced BP increase was attenuated ( Figure 1A ). To evaluate whether c-Src effects are specific for Ang II, we also examined NE-induced pressor effects in c-Src-deficient mice. NE increased in SBP in both c-Src 
CGP077675 Normalizes Blood Pressure in Ang IIInfused Mice
In another series of experiments, c-Src +/+ mice were infused with Ang II in the absence and presence of CGP077675. Ang IIinduced increase in SBP was reduced by CGP077675 ( Figure 1C ). Within 5 days of CGP077675, SBP was normalized to levels as in vehicle-treated mice. BP responses observed by tail-cuff measurement were similar to those measured by telemetry ( Figure S1 ).
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Ang II-infused c-Src +/+ and c-Src +/− mice exhibited reduced mechanical stress versus vehicle-infused counterparts in response to stepwise increments of intraluminal pressure. No additional shift was observed in the mechanical stress curves from the CGP077675-treated Ang II-infused mice.
c-Src and Aortic Structure
Photomicrographs of Masson trichrome-stained cross-sections of thoracic aorta showed a significant increase in the media thickness with Ang II infusion in c-Src +/+ and c-Src +/− mice ( Figure 3 ). Aortic thickening is evidenced by irregularities in the pattern and the distances between each concentric elastic lamina intermingled with smooth muscle cell layers ( Figure 3A) . Morphometric quantitative analysis showed that the effects of Ang II were attenuated by CGP077675 but not by c-Src deficiency ( Figure 3B ). Slight thickening of the adventitial layer with perivascular fibrosis surrounding the vessel wall was also observed in some Ang II-infused mice. Dihydroethidium fluorescence images show increased ROS generation in aortas from Ang II-infused mice, an effect attenuated by CGP077675 and c-Src deficiency ( Figure 4A ). Lucigenin-derived luminescence was increased in both aorta ( Figure 4B ) and mesenteric arteries ( Figure 4C ) from Ang II-infused c-Src +/+ mice. CGP077675 reduced the increase of superoxide generation. Ang II infusion did not induce superoxide production vessels from c-Src +/− mice. NE did not induce activation of vascular NADPH oxidase ( Figure 4B ).
Plasma thiobarbituric acid-reactive substance levels (products of lipid peroxidation), measured as an index of systemic oxidative stress, were higher in Ang II-infused c-Src +/+ mice versus vehicle-treated counterparts ( Figure 4D Underlying molecular mechanisms whereby c-Src influences endothelium-dependent vasodilation were investigated by probing endothelial nitric oxide (eNOS) expression and phosphorylation. No differences were observed in eNOS protein expression ( Figure S6A ) and phosphorylation at Ser 1178 (activation residue; Figure S6B ) in arteries from c-Src +/+ and c-Src +/− mice treated with vehicle or Ang II. CGP077675 did not influence eNOS. Expression of caveolin-1, a negative regulator of eNOS, was increased in Ang II-infused c-Src +/+ mice, effects that were inhibited by CGP077675 ( Figure S6C ). Caveolin-1 was unaffected by Ang II in c-Src +/− mice versus vehicle-infused counterparts. Levels of urinary nitrite/nitrate (marker of systemic NO production) were not different between groups ( Figure S6D ).
c-Src Expression and Phosphorylation
Total c-Src protein content was reduced in tissues from c-Src +/− mice ( Figure S7A ) and was not influenced by CGP077675 (FigureS7B and S7C) . Ang II-induced vascular c-Src phosphorylation ( Figure 5A ; Figure S8A ) in WT mice Figure 5C ). Ang II increased vascular JNK (c-Jun N-terminal kinase) phosphorylation, an effect that was inhibited by CGP077675. Ang II failed to increase JNK phosphorylation in c-Src +/− mice ( Figure 5D ).
NE Does not Induce c-Src or ERK1/2 Phosphorylation
The effect of NE infusion on c-Src and ERK1/2 phosphorylation was evaluated in aortas from c-Src +/+ and c-Src +/− mice ( Figure S9 ). NE had no effect on vascular c-Src or ERK1/2 phosphorylation.
Molecular Markers of Inflammation and Fibrosis in Ang II-Induced Hypertension
Proinflammatory pathways were investigated by probing for COX2 (ciclooxigenase 2), VCAM-1 (vascular cell adhesion molecule 1), and PAI-1 (plasminogen activator inhibitor 1). As shown in Figure 6A 
Histopathology of the Heart
Hypertension-associated cardiac damage was also assessed by evaluating cardiac collagen accumulation and interstitial fibrosis by Sirius Red and Masson trichrome staining, respectively. Representative heart sections are shown in Figure S11 . Hearts from Ang II-infused mice displayed excessive deposition of collagen with fibrotic areas and positive staining for CD68, identifying the presence of mononuclear inflammatory cell infiltrate. Pharmacological inhibition of c-Src exacerbated the fibrotic and inflammatory processes induced by Ang II, because hearts from mice treated with CGP077675 stained highly positive for CD68 and presented more extensive areas of collagen accumulation and fibrosis. Increased collagen deposition and fibrosis were also evident in Ang II-infused c-Src +/− mice.
Discussion
Major finding from the present study demonstrate that pharmacological and genetic inactivation of c-Src prevents development of hypertension in Ang II-infused mice. Endothelial and cardiac dysfunction were ameliorated by c-Src inhibition, processes associated with reduced oxidative stress and decreased activation of ERK1/2, JNK, and proinflammatory signaling pathways. Whereas vascular functional responses were ameliorated by c-Src downregulation, Ang II-induced cardiovascular remodeling and fibrosis were amplified by c-Src inactivation or deficiency, as evidenced by increased vascular media thickness, CSA, and fibronectin expression in resistance and conduit arteries. Similar trends were evident in the hearts of Ang II-induced hypertensive mice where cardiac fibrosis was also exaggerated by CGP077675 or c-Src deficiency. These findings suggest that although c-Src inhibition prevents development of hypertension, improves endothelial and cardiac function, reduces oxidative stress, and normalizes vascular signaling, it has little beneficial effect on cardiovascular remodeling or fibrosis. Our study suggests a divergent role for c-Src in Ang II-dependent hypertension, where c-Src may be more important in regulating redoxsensitive cardiac and vascular function rather than processes associated with cardiovascular fibrosis and structure. These novel insights underscore the complex role of c-Src in Ang II-induced hypertension and suggest that c-Src inhibition as a potential therapeutic modality should be considered with caution, because although it improves endothelial and cardiac function, it may aggravate cardiovascular fibrosis. Ang II, an important vasoactive hormone, mediates effects through multiple complex signaling pathways that regulate vascular cell contraction/relaxation, growth, apoptosis, senescence, fibrosis, and inflammation, processes involved in the regulation of vascular function and structure. [8] [9] [10] [11] Central to these events is c-Src and ROS, which are tightly interlinked. [21] [22] [23] We previously demonstrated in human and rodent VSMCs that Ang II-induced increase in [Ca 2+ ] i , phosphorylation of MAPKs, regulation of RhoA/Rho kinase, and activation of Nox are c-Src dependent. [23] [24] [25] Although extensive in vitro evidence indicates a critical role for c-Src in Ang II signaling in cardiovascular cells, the pathophysiological significance of c-Src in hypertension and associated cardiovascular injury, in vivo, requires further investigation.
Using pharmacological and genetic approaches to inhibit c-Src activation, we interrogated the role of this nonreceptor tyrosine kinase in the development of hypertension. Ang II induced a significant increase in BP in c-Src +/+ mice, responses that were associated with increased activation of vascular c-Src. These effects were inhibited when c-Src activity was downregulated. To support these findings, CGP077675, a pharmacological c-Src inhibitor of the pyrrolopyrimidine class that acts on the autophosphorylation site of the tyrosine kinase suppressing its activity, 30 exhibited antihypertensive effects in Ang II-infused mice. Similar results were reported for SU6656, a nonspecific Src family kinase inhibitor. 28 c-Srcassociated pressor actions seem to be highly regulated by specific vasoactive agents because NE-induced hypertension was unaffected by c-Src deficiency.
The BP-lowering effect of CGP077675 was rapid, occurring within 2 days after treatment, indicating that c-Src inhibitory effects likely occur through increased endothelium-dependent vasodilation, typically associated with acute BP changes. In support of this, the reduced acetylcholine-induced vasorelaxation in c-Src +/+ mice was improved in CGP077675-treated mice, indicating vasoprotection by c-Src inhibition. Molecular processes underlying these actions may relate to oxidative inactivation of NO as previously reported 34 and are supported by our findings of no change in eNOS phosphorylation with concomitant increase in ROS production. It may also be possible that c-Src influences eNOS indirectly by upregulating caveolin-1, a negative modulator of eNOS. 35 This may be especially important in the endothelium, which is rich in caveolin-1 and eNOS.
36 CGP077675 normalized caveolin-1 expression in Ang II-infused mice with associated improvement in endothelial function and blood pressure reduction. Our findings differ to those previously reported where c-Src was found to induce activation of eNOS through PI3 kinase/Akt. However, those studies were performed in cultured endothelial cells. 37 Ang II-induced hypertension was associated with increased systemic and vascular ROS generation as evidenced by increased levels of plasma plasma thiobarbituric acidreactive substances and H 2 O 2 and enhanced vascular NADPH oxidase-derived superoxide production. These findings confirm previous studies demonstrating an important pathophysiological role for oxidative stress in the development of hypertension and associated vascular dysfunction. CGP077675 normalized redox status in Ang II-infused mice, indicating a role for c-Src in oxidative stress in hypertension. Because endothelial function is regulated not only by NO-dependent mechanisms but also by redox-sensitive pathways, the improved endothelial function in CGP077675-treated mice may relate, at least in part, to reduced oxidative stress. 34 We previously demonstrated a close interaction between Nox, ROS, and c-Src in human and rat VSMCs and found that c-Src was both upstream and downstream of Nox. 16, [21] [22] [23] We showed that this occurs through c-Src-induced phosphorylation of p47phox and increased abundance of NADPH oxidase subunits. 16 The c-Src-ROS link in VSMCs has recently been highlighted 38 and is increasingly being recognized as a feed forward loop whereby oxidative stress is amplified when c-Src is activated. Interrupting this loop by inhibiting c-Src dampens activation of downstream redox signaling including MAPK and proinflammatory transcription factors. This is evidenced here in our in vivo study where increased ROS generation, MAPK phosphorylation, and enhanced COX2 expression in hypertensive mice were normalized or attenuated by c-Src downregulation. c-Src seems to be especially important in Ang II-induced ERK1/2 activation, because c-Src inhibition reduced phosphorylation of ERK1/2 below basal levels. The critical role of c-Src in these events is underscored by the fact that even partial reduction of c-Src (in heterozygous mice) is enough to normalize signaling in Ang II-infused mice.
c-Src regulatory effects of Ang II are not generalized phenomena, because phosphorylation of p38MAPK was not altered by c-Src deficiency. These findings are in contrast to our earlier studies in aldosterone-treated vascular smooth muscle cells, where we found that p38MAPK activation is c-Src sensitive. 39 Hence, c-Src actions are agonist/receptor sensitive, highly regulated, and target protein specific.
At the vascular level, hypertension is characterized not only by endothelial dysfunction but also by vascular structural (remodeling) and mechanical changes. 40, 41 In particular, small arteries in hypertension undergo inward eutrophic remodeling, and hypertrophic remodeling with associated impaired mechanical properties. 2, 40 Increased collagen deposition, fracturing of elastin, calcium deposition, proliferation, rearrangement, and hypertrophy of VSMCs and inflammation contribute to these processes. [40] [41] [42] Mechanically, vessels become stiffer and less distensible. In hypertension, vascular remodeling has an important Ang II-dependent component as evidenced by clinical investigations demonstrating that angiotensin-converting enzyme (ACE) inhibition or AT 1 receptor blockers prevented or reversed structural and mechanical changes. [42] [43] [44] In our study, significant vascular alterations were observed in both resistance and conduit arteries. Small mesenteric arteries of Ang II-infused c-Src +/+ mice exhibited increased media thickness, CSA, and vascular stiffness, responses that also present in c-Src +/− mice. These findings suggest that Ang II-induced remodeling may be independent of c-Src activation. In aorta, media thickness was also increased by Ang II in both c-Src
and c-Src +/− mice. CGP077675 did not improve structural and mechanical changes, and in fact hypertrophy was exaggerated in small arteries. However, differential effects were observed in aorta, where CGP077675 prevented the increase in media thickness. At the molecular level, vascular fibronectin expression was similarly increased by Ang II in c-Src +/+ and c-Src-deficient mice. Moreover, CGP077675 exacerbated fibronectin expression in Ang II-infused mice. To further support our findings that Ang II-induced remodeling is likely c-Src independent, we observed that collagen deposition, fibrosis, and inflammation were variably increased in hearts from c-Src-deficient mice and in mice treated with CGP077675. These findings suggest that c-Src may not play a major role in cardiovascular growth or fibrosis and may not contribute significantly to structural changes elicited by Ang II, at least in the model studied here.
PCNA, a marker of cell proliferation, was not significantly altered in c-Src
-treated or CGP077675-treated mice. Reasons for the additional trophic and profibrotic effects of CGP077675 are unclear, but may relate to effects on cell cycle regulators other than PCNA because expression and activity of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 are reduced by the c-Src inhibitor resulting in cell cycle progression. 45 Moreover, we cannot exclude the possibility that CGP077675 may have some nonspecific effects because it can also inhibit other Src isoforms. 46 
Perspectives
Our results provide in vivo evidence to show that c-Src plays an important role in the pathophysiology of Ang II-dependent hypertension through processes that involve ROS and MAPK. Although vascular and cardiac functional alterations and redox-dependent processes are c-Src dependent, arterial remodeling and cardiac fibrosis are c-Src independent. Although c-Src may be an interesting potential therapeutic target to reduce blood pressure and improve cardiovascular function, caution is warranted on the possible profibrotic cardiovascular effects of c-Src inhibition. 
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• c-Src effects may be Ang II specific, because norepinephrine-induced hypertension was unaffected by c-Src inhibition.
• Ang II-induced cardiovascular fibrosis and remodeling are not protected by c-Src inhibition.
What Is Relevant?
• In Ang II-induced hypertension, c-Src plays a role in functional but not structural changes in the cardiovascular system.
• c-Src may have differential cardiovascular effects, both protective and injurious, in Ang II-induced hypertension. 
Methods Animals
The study was approved by the Animal Ethics Committee of the Ottawa Hospital Research Institute, University of Ottawa and carried out according to the recommendations of the Canadian Council for Animal Care. Homozygous mice for a disruption in the c-Src gene were generated from a c-Src +/-F1 cross and were genotyped by polymerase chain reaction. 36 In this study, wild-type (c-Src +/+ ) and heterozygous (c-Src +/-) male mice were used at 8 weeks of age). Mice were infused with Ang II (400 ng/kg/min) or norepinephrine (NE; 3.8 µg/Kg/min) for 10-12 days (ALZET 1002 osmotic mini-pump). A second group of Ang II-infused c-Src +/+ mice received daily subcutaneous injection of the c-Src inhibitor, CGP077675, (25 mg/Kg/day, Novartis), starting 5 days after the onset of Ang II infusion. The dose of CGP077675 was selected based on published data.
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CGP077675 is a potent and selective Src family kinase inhibitor. It inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src with an IC50 of 5-20 and 40 nM, respectively. At the end of the treatment period, mice were euthanized by isoflurane inhalation. Plasma, aorta, mesenteric arterial bed, and heart were collected for analysis.
Systolic blood pressure measurement SBP was assessed by tail-cuff plethysmography and telemetry. For tail-cuff plethysmography, mice were trained to the apparatus (Visitech Systems model BP-2000) for consecutive days until stable readings were obtained. After pretreatment values (baseline) were measured, osmotic mini-pumps were implanted and systolic blood pressure (SBP) was assessed daily or three times weekly for the duration of the experimental protocols. For telemetry measurements, mice were anesthetized by isoflurane inhalation and the telemetry probe (TA11-PA20; Data Sciences International) was implanted in the carotid artery. Mice were allowed a 6 day recovery period before initiating blood pressure recording. Osmotic mini-pumps were implanted 2 days prior the probe surgeries. CGP077675 treatment was started 8 days after the onset of Ang II infusion. Signals were collected for 10 seconds every 5 minutes for 4 days using a model RLA1020 receiver with an eight-channel data exchange matrix an APR-1 ambient pressure monitor and a DataQuest ART Silver 2.1 acquisition system.
3-5
Echocardiography Cardiac geometry and function were evaluated with a Sonos 5500 (Philips) echo Doppler equipped with a 15-to 6-L 6 to 15-MHz ultraband Intraoperative Linear Array probe. All studies were performed on lightly anesthetized (2% isoflurane, 5 min) mice maintained at 37°C. Mmode-derived measures of left ventricle (LV) area were obtained, using the leading edge-toleading-edge convention. Temporal changes between LV internal diameter at systolic (LVIDs) and LV internal diameter at diastolic (LVIDd) were used for the calculation of percent shortening fraction, as follows [(LVIDd diameter− LVIDs)/ LVIDs]×100. Three heart beats were averaged for each measurement. 6 
Plasma Biochemistry
Blood was collected immediately prior to sacrifice by cardiac puncture. Plasma glucose, triglycerides, and cholesterol were determined by automated analyzer (Beckman Coulter AU5800).
Lucigenin-enhanced chemiluminescence assay
Vascular ROS generation was measured by a luminescence assay with lucigenin as the electron acceptor and NADPH as the substrate. Aortic segments and mesenteric arterial beds were homogenized in assay buffer (in mmol/L: 50 KH 2 PO 4 , 1 EGTA, and 150 sucrose, pH 7.4) with a glass-to-glass homogenizer. The assay was performed with 100 µL of sample, 1.25 µL of lucigenin (5 µmol/L), 25 µL of NADPH (0.1 mmol/L) and assay buffer to a total volume of 250 µL. Luminescence was measured for 30 cycles of 18 seconds each by a luminometer (Lumistar Galaxy, BMG Labtechnologies, Germany). Basal readings were obtained prior to the addition of NADPH to the assay. The reaction was started by the addition of the substrate. Basal and buffer blank values were subtracted from the NADPH-derived luminescence. Superoxide anion production was expressed as relative luminescence units (RLU)/µg protein.
Detection of reactive oxygen species production in aorta by dihydroethidium Dihydroethidium (DHE) fluorescence was used to detect ROS production within the vessel wall. Frozen aortic rings were cut into 10 µm-thick sections and placed on a glass slide. Each section was incubated with 100 µL DHE (2 µmol/L in fresh Krebs solution) in the dark, at 37°C for 30 min. DHE fluorescence was detected with a 563-nm long-pass filter after excitation at 543 nm, and images were obtained with a Zeiss LSM confocal microscope (CarlZeiss Jena GmbH, Jena, Germany) equipped with a krypton/argon laser. Five aortas of each group were studied and three areas per aortic ring were analyzed.
Measurement of plasma lipid peroxidation products
Plasma lipid peroxidation was determined by quantifying thiobarbituric acid-reactive substances (TBARS). Plasma samples were mixed with 2% butylated hydroxytoluene and quintanilla reagent (26 mmol/L thiobarbituric acid and 15% trichloroacetic acid). The mixture was boiled for 15 min. Subsequently, the mixture was cooled and centrifuged at 3000 g for 10 min. TBARS formed in each sample was assessed by measuring optical density of the supernatant at 535 nm with an absorbance microplate reader (BioTek ELx808). In parallel, MDA (malondialdehyde) standards were diluted in the range of 0-6 nmol/mL. TBARS were calculated by plotting the obtained absorbance against an MDA concentration standard curve.
Measurement of plasma H 2 O 2 levels
Plasma H 2 O 2 was assessed with Amplex Red assay kit (Molecular Probes, by Life Technologies). Plasma samples (2µL) were incubated with the reaction mixture according to manufacturer specifications. A microplate reader was used for absorbance at 560 nm. The kinetics of the reaction was followed at multiple time points. H 2 O 2 plasma levels, obtained at 15 min reaction time point, are presented in µmol/L.
Preparation of small mesenteric arteries for assessment of vascular function, structure and mechanical properties
In this study we used resistance arteries, important in blood pressure regulation. Second order branches of the superior mesenteric artery (2 to 3 mm in length) were slipped onto 2 glass microcannulae, one of which was positioned until vessel walls were parallel, in a pressure myograph (Living Systems, Burlington, Vermont). Vessel segments were equilibrated in KrebsHenseleit-modified physiological salt solution (in mmol/L: 120 NaCl, 25 NaHCO 3 , 4.7 KCl, 1.18 KH 2 PO 4 , 1.18 MgSO 4 , 2.5 CaCl 2 , 0.026 EDTA, and 5.5 glucose) at 37°C, continuously bubbled with 95% O 2 and 5% CO 2, pH 7.4, under constant intraluminal pressure (45 mmHg) . At the beginning of each experiment, arteries were contracted with 10 µmol/L NE or 90 mmol/L KCl to test for functional integrity. The endothelial integrity was assessed by relaxation in response to 1 µmol/L acetylcholine (ACh) of NE pre-contracted arteries. Endothelium-dependent relaxation was assessed by concentration-response curves to ACh (1 nmol/L to 100 µmol/L) in vessels precontracted with NE at a concentration to achieve approximately 70% of maximal response (1 µmol/L). Endothelium-independent relaxation was assessed by the concentration-response curves to sodium nitroprusside (SNP, 1 nmol/L to 100 µmol/L). Contractile responses mediated by Ang II (10 pmol/L to 100 nmol/L) were evaluated in endothelium-intact arteries. After the vascular function protocols, vascular structure and mechanical studies were assessed under calcium-free conditions to eliminate the effects of myogenic tone. Vessels were perfused for 30 min with Ca 2+ free Krebs solution containing 10 mmol/L EGTA. Measurement of media thickness and lumen diameter were taken at stepwise increments of luminal pressure (3 to 140 mmHg). Vascular structural and mechanical parameters were calculated as previously described.
5
Urinary nitric oxide measurement Spot urine was kept at -80°C until further analysis. Total nitrate/nitrite levels were measured in the urine as nitric oxide metabolites using the Nitrate/Nitrite Colorimetric Assay Kit (Cayman Chemical, Ann Arbor, USA).
Western blotting
Total protein was extracted from aorta and mesenteric arterial bed. Frozen tissues were homogenized in 50 mmol/L Tris-HCl (pH 7.4) lysis buffer containing 1% Nonited P-40, 0.5% sodium deoxycholate, 150 mmol/L NaCl, 1 mmol/L EDTA, 0.1% SDS, 2 mmol/l sodium orthovanadate (Na 3 VO 4 ), 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 µg/mL pepstatin A, 1 µg/mL leupeptin and 1 µg/mL aprotinin. Total protein extracts were cleared by centrifugation at 10 000 rpm for 10 min and the pellet was discarded. Proteins from homogenates of vascular tissues (20 µg) were separated by electrophoresis on a polyacrylamide gel (10%), and transferred onto a nitrocellulose membrane. Nonspecific binding sites were blocked with 5% skim milk or 1% bovine serum albumin (BSA) in Tris-buffered saline solution with 0.01 % Tween for 1 hour at room temperature. Membranes were then incubated with specific antibodies overnight at 4°C. Antibodies were as follows: anti-c-Src anti-cyclooxygenase (COX-2, Cayman); anti-fibronectin (Sigma). Antibodies to β-actin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used as internal housekeeping control (Sigma). After incubation with secondary antibodies, signals were revealed with chemiluminescence, visualized by autoradiography and quantified densitometrically. We used 2 housekeeping proteins, β-actin or GAPDH, to normalise our candidate protein of interest. Reasons for using 2 housekeeping proteins relate to the fact that in some instances there was mild variability in protein content and as such we selected the housekeeping protein (β-actin or GAPDH) that was most stable in the different experimental conditions.
Histological and immunohistochemical analyses
For histological and immunohistochemical analyses, heart and aorta were fixed in 4 % paraformaldehyde and processed for paraffin embedding. Sections (5 µm thick) were stained with Masson's trichrome or Sirius Red. The degree of vascular remodeling (medial thickness and perivascular fibrosis) was evaluated in thoracic aortas. For the morphometric analysis in crosssections of aorta, the wall thickness was measured in four regions and the values were averaged. For immunohistochemical staining in heart sections, heat-induced epitope retrieval was performed at 110 o C for 12 min with tris-EDTA buffer (pH 9.0). To localize mouse macrophages, CD68 [clone KP1] primary antibody (dilution 1/250, Biocare) was used. Hematoxylin was performed as a nuclear counterstain.
Statistical Analysis
Data are presented as means ± SEM. Groups were compared using one-way ANOVA, two-way ANOVA or t-test as appropriate. P<0.05 was considered significant. Photomicrographs of heart sections were processed for Sirius Red, Masson's trichrome, and immunohistochemistry of CD68 (left to right). magnifications of x100, x100, and x200 respectively
